Cell-based therapy in thin endometrium and Asherman syndrome
Abstract Numerous treatment strategies have so far been proposed for treating refractory thin endometrium either without or with the Asherman syndrome. Inconsistency in the improvement of endometrial thickness is a common limitation of such therapies including tamoxifen citrate as an ovulation induc...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-01-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-021-02698-8 |
| _version_ | 1819281499097137152 |
|---|---|
| author | Nastaran Gharibeh Leili Aghebati-Maleki Javad Madani Ramin Pourakbari Mehdi Yousefi Javad Ahmadian Heris |
| author_facet | Nastaran Gharibeh Leili Aghebati-Maleki Javad Madani Ramin Pourakbari Mehdi Yousefi Javad Ahmadian Heris |
| author_sort | Nastaran Gharibeh |
| collection | DOAJ |
| description | Abstract Numerous treatment strategies have so far been proposed for treating refractory thin endometrium either without or with the Asherman syndrome. Inconsistency in the improvement of endometrial thickness is a common limitation of such therapies including tamoxifen citrate as an ovulation induction agent, acupuncture, long-term pentoxifylline and tocopherol or tocopherol only, low-dose human chorionic gonadotropin during endometrial preparation, aspirin, luteal gonadotropin-releasing hormone agonist supplementation, and extended estrogen therapy. Recently, cell therapy has been proposed as an ideal alternative for endometrium regeneration, including the employment of stem cells, platelet-rich plasma, and growth factors as therapeutic agents. The mechanisms of action of cell therapy include the cytokine induction, growth factor production, natural killer cell activity reduction, Th17 and Th1 decrease, and Treg cell and Th2 increase. Since cell therapy is personalized, dynamic, interactive, and specific and could be an effective strategy. Despite its promising nature, further research is required for improving the procedure and the safety of this strategy. These methods and their results are discussed in this article. |
| first_indexed | 2024-12-24T01:00:39Z |
| format | Article |
| id | doaj.art-27b3e721475240ecad72ec53eb669fef |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-12-24T01:00:39Z |
| publishDate | 2022-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-27b3e721475240ecad72ec53eb669fef2022-12-21T17:23:22ZengBMCStem Cell Research & Therapy1757-65122022-01-0113111310.1186/s13287-021-02698-8Cell-based therapy in thin endometrium and Asherman syndromeNastaran Gharibeh0Leili Aghebati-Maleki1Javad Madani2Ramin Pourakbari3Mehdi Yousefi4Javad Ahmadian Heris5Student’s Research Committee, Tabriz University of Medical SciencesImmunology Research Center, Tabriz University of Medical SciencesStem Cell Research Center, Tabriz University of Medical SciencesStudent’s Research Committee, Tabriz University of Medical SciencesStem Cell Research Center, Tabriz University of Medical SciencesDepartment of Allergy and Clinical Immunology, Pediatric Hospital, Tabriz University of Medical SciencesAbstract Numerous treatment strategies have so far been proposed for treating refractory thin endometrium either without or with the Asherman syndrome. Inconsistency in the improvement of endometrial thickness is a common limitation of such therapies including tamoxifen citrate as an ovulation induction agent, acupuncture, long-term pentoxifylline and tocopherol or tocopherol only, low-dose human chorionic gonadotropin during endometrial preparation, aspirin, luteal gonadotropin-releasing hormone agonist supplementation, and extended estrogen therapy. Recently, cell therapy has been proposed as an ideal alternative for endometrium regeneration, including the employment of stem cells, platelet-rich plasma, and growth factors as therapeutic agents. The mechanisms of action of cell therapy include the cytokine induction, growth factor production, natural killer cell activity reduction, Th17 and Th1 decrease, and Treg cell and Th2 increase. Since cell therapy is personalized, dynamic, interactive, and specific and could be an effective strategy. Despite its promising nature, further research is required for improving the procedure and the safety of this strategy. These methods and their results are discussed in this article.https://doi.org/10.1186/s13287-021-02698-8Cell therapyEndometriumAsherman syndrome |
| spellingShingle | Nastaran Gharibeh Leili Aghebati-Maleki Javad Madani Ramin Pourakbari Mehdi Yousefi Javad Ahmadian Heris Cell-based therapy in thin endometrium and Asherman syndrome Stem Cell Research & Therapy Cell therapy Endometrium Asherman syndrome |
| title | Cell-based therapy in thin endometrium and Asherman syndrome |
| title_full | Cell-based therapy in thin endometrium and Asherman syndrome |
| title_fullStr | Cell-based therapy in thin endometrium and Asherman syndrome |
| title_full_unstemmed | Cell-based therapy in thin endometrium and Asherman syndrome |
| title_short | Cell-based therapy in thin endometrium and Asherman syndrome |
| title_sort | cell based therapy in thin endometrium and asherman syndrome |
| topic | Cell therapy Endometrium Asherman syndrome |
| url | https://doi.org/10.1186/s13287-021-02698-8 |
| work_keys_str_mv | AT nastarangharibeh cellbasedtherapyinthinendometriumandashermansyndrome AT leiliaghebatimaleki cellbasedtherapyinthinendometriumandashermansyndrome AT javadmadani cellbasedtherapyinthinendometriumandashermansyndrome AT raminpourakbari cellbasedtherapyinthinendometriumandashermansyndrome AT mehdiyousefi cellbasedtherapyinthinendometriumandashermansyndrome AT javadahmadianheris cellbasedtherapyinthinendometriumandashermansyndrome |